dinoprost and Intestinal-Diseases

The dynamics of the level of prostaglandins E and F was studied in 45 patients with bacterial intestinal infections. It was established that during the acute period of the disease their content showed a significant increase. Inclusion of the indomethacin (a prostaglandin inhibitor) in the complex pathogenetic treatment of intestinal infections promotes early disappearance of pathological symptoms of the disease.

Topics: Acute Disease; Bacterial Infections; Child, Preschool; Convalescence; Dinoprost; Drug Evaluation; Humans; Indomethacin; Infant; Intestinal Diseases; Prostaglandins E

Fertility parameters of 10 men with chronic inflammatory bowel disease under treatment with sulfasalazine for at least 5 years were compared to those of 19 control subjects. Seminal parameters examined included ejaculate volume, sperm number and concentration, sperm motility index, sperm viability, pH, zinc concentration, prostaglandins E and F2-alpha, prolactin and 7 classes of sperm morphology. In addition, plasma concentrations of follicle-stimulating hormone, luteinizing hormone, testosterone and prolactin were noted. The data indicate that sulfasalazine therapy reduces semen quality and that this effect can be reversed upon removal from therapy. This reversal is independent of seminal prostaglandin concentrations.

Topics: Adult; Dinoprost; Dinoprostone; Fertility; Follicle Stimulating Hormone; Humans; Inflammation; Intestinal Diseases; Luteinizing Hormone; Male; Prolactin; Prostaglandins; Prostaglandins E; Prostaglandins F; Semen; Sperm Count; Sperm Motility; Spermatozoa; Sulfasalazine; Testosterone; Zinc

Intestinal mucosal damage was produced in rats by the s.c. administration of indomethacin (10 mg/kg). The number and severity of the small intestinal mucosal lesions was recorded. Different doses of prostacyclin (PGI2), 7-oxo-PGI2 and 17-aza-PGF2 alpha (0.25-0.5-1.00 mg/kg) were given i.p. at the time of administration of indomethacin. The effects of these compounds were studied on the number and severity of the small intestinal mucosal lesions. It was shown that (1) all tested compounds inhibited the number and severity of the intestinal mucosal lesions, however, to different extent; (2) the inhibition of the development of small intestinal mucosal damage displayed a dose-response relationship; (3) 17-aza-PGF2 alpha was found to have the most potent effect on the development of the intestinal lesions as well as on the development of gastric mucosal damage produced by ethanol.

Topics: Animals; Dinoprost; Epoprostenol; Indomethacin; Intestinal Diseases; Intestinal Mucosa; Prostaglandins F, Synthetic; Rats; Ulcer

Topics: Animals; Body Weight; Diarrhea; Dinoprost; Dinoprostone; Inflammation; Intestinal Diseases; Male; Prostaglandins E; Prostaglandins F; Rats; Rats, Inbred Strains; Time Factors